Michael Lim
Alliance for Clinical Trials in Oncology · Johns Hopkins University · Johns Hopkins Department of Neurosurgery
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Lim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:07 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06325683 · Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaNational Cancer Institute (NCI) · suspended · Progressive Glioblastoma, Recurrent Glioblastoma · principal investigator
- Ph1NCT03707457 · Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of GlioblastomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Glioblastoma, Glioblastoma Multiforme · principal investigator
- Ph1NCT01950195 · SRS (Stereotactic Radiosurgery) Plus IpilimumabSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Newly Diagnosed Melanoma Metastases in the Brain and Spine · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 11 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT06325683
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 10:07 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.JAMA Oncol · 20201,288 citationsRCR 55.9
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.Lancet Oncol · 2017953 citationsRCR 30.9
- Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.Neuro Oncol · 2022489 citationsRCR 33.3
- 482 citationsRCR 43.2
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.Neuro Oncol · 2018408 citationsRCR 13.9
- Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.Clin Cancer Res · 201793 citationsRCR 3.0
- Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.Clin Cancer Res · 202239 citationsRCR 2.7
- Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.J Clin Oncol · 20268 citationsRCR 4.0